Drug Approval | November 23, 2022
USFDA grants priority review of BLA for dengue vaccine TAK-003
If approved, TAK-003 has the potential to become an important dengue prevention option for healthcare providers
If approved, TAK-003 has the potential to become an important dengue prevention option for healthcare providers
Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses
Quinten Health will announce in the coming months strategic partnerships with big pharma companies and data owners to launch the first disease modeling platforms.
CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine
Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares
Subscribe To Our Newsletter & Stay Updated
